Investigation of polymorphisms in pre-eclampsia related genes VEGF and IL1A

Vanessa Resende Souza Silva1, Fernanda Caroline Soardi, Sarah Cristina Sato Vaz Tanaka

  • 1Disciplina de Genética, Instituto de Ciências Biológicas e Naturais, Universidade Federal do Triângulo Mineiro, Praça Manoel Terra 330 Centro, 38015050, Uberaba, MG, Brazil.

Insights

Genetic variations in interleukin 1 alpha are linked to pre-eclampsia risk. The rs3783550 polymorphism indicates a higher probability of developing pre-eclampsia in women with allele A.

Area of Science:

  • Obstetrics and Gynecology
  • Genetics
  • Immunology

Background:

  • Pre-eclampsia (PE) is a pregnancy syndrome with unknown causes, potentially involving genetic factors.
  • Vascular Endothelial Growth Factor (VEGF) and Interleukin 1 Alpha (IL1A) gene polymorphisms are implicated in PE pathophysiology.
  • VEGF regulates endothelial cells, while IL1A triggers inflammatory responses contributing to endothelial dysfunction in PE.

Purpose of the Study:

  • To investigate the association of VEGF G-634C and IL1A rs3783550 polymorphisms with pre-eclampsia in a Brazilian cohort.
  • To identify potential genetic markers for pre-eclampsia susceptibility.

Main Methods:

  • Genotyping of VEGF G-634C using PCR-RFLP (BsmFI enzyme).
  • Genotyping of IL1A rs3783550 using allele-specific PCR.
  • Analysis of DNA fragments via agarose and/or polyacrylamide gel electrophoresis.

Main Results:

  • No significant association was found between the VEGF G-634C polymorphism and pre-eclampsia.
  • A significant correlation was observed between the IL1A rs3783550 polymorphism and pre-eclampsia.
  • Women with the IL1A rs3783550 allele A demonstrated an increased likelihood of developing pre-eclampsia.

Conclusions:

  • The IL1A rs3783550 polymorphism is a potential genetic marker for pre-eclampsia.
  • Interleukin 1 Alpha gene variations may serve as a diagnostic and monitoring tool for pre-eclampsia patients.
Abstract

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
152
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K